|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on June 14, 2002; DOI 10.1182/blood-2002-02-0388.
HEMATOPOIESIS
From the Center for Blood Research, and the Division of
Immunology, Children's Hospital, and the Department of Pediatrics,
Harvard Medical School, Boston, MA.
Wiskott-Aldrich syndrome (WAS) is an X-linked disease characterized
by thrombocytopenia, eczema, and various degrees of immune deficiency.
Carriers of mutated WASP have nonrandom X
chromosome inactivation in their blood cells and are disease-free. We
report data on a 14-month-old girl with a history of WAS in her family who presented with thrombocytopenia, small platelets, and immunologic dysfunction. Sequencing of the WASP gene showed that the
patient was heterozygous for the splice site mutation previously found in one of her relatives with WAS. Sequencing of all WASP exons revealed
no other mutation. Levels of WASP in blood mononuclear cells
were 60% of normal. Flow cytometry after intracellular staining of
peripheral blood mononuclear cells with WASP monoclonal antibody revealed both WASPbright and WASPdim
populations. X chromosome inactivation in the patient's blood cells
was found to be random, demonstrating that both maternal and paternal
active X chromosomes are present. These findings indicate that the
female patient has a defect in the mechanisms that lead in disease-free
WAS carriers to preferential survival/proliferation of cells bearing
the active wild-type X chromosome. Whereas the patient's lymphocytes
are skewed toward WASPbright cells, about 65% of her
monocytes and the majority of her B cells (CD19+) are
WASPdim. Her naive T cells
(CD3+CD45RA+) include WASPbright
and WASPdim populations, but her memory T cells
(CD3+CD45RA Wiskott was the first to describe male individuals
from a single family with thrombocytopenia, eczema, and bloody diarrhea in 1937.1 In 1954, Aldrich established X-linked
inheritance of the disease.2 Subsequently the disease was
called Wiskott-Aldrich syndrome (WAS). In its fully expressed form,
boys affected with WAS present at an early age with severe
thrombocytopenia, eczema, and various degrees of immunodeficiency.
Profound thrombocytopenia with small platelets is present in all
patients. Clinical classification is based on severity of eczema and
immunodeficiency.3 Severe cases are additionally
characterized by higher incidences of autoimmune and
lymphoproliferative diseases.4-6 The primarily affected
cells in WAS patients are lymphocytes and platelets. Both cellular and humoral immunity are impaired. Defects include deficient response of
lymphocytes to mitogens and decreased levels of IgG and
IgM.7 In addition, antibody titers to polysaccharides are
often depressed.8-11 The profoundly decreased platelet
number and small size are due mainly to destructive events occurring in
the circulation.12-14
The gene, mutations of which are responsible for the phenotype,
was mapped to Xp11.23 and consists of 12 exons encoding a protein of
502 amino acids (WASP).15,16 WASP is expressed solely in
blood cells; it is a multidomain protein that participates in
cytoskeleton reorganization17 (for a review, see Higgs and Pollard18).
The severity of immune disease in WAS patients correlates in many cases
with specific mutations and with the level of WASP in blood
cells. Whereas patients with severe disease frequently lack detectable
WASP in blood cells, most patients with mild disease have measurable
levels of WASP in peripheral blood mononuclear cells
(PBMCs).19-22
Females who are carriers of a defective WASP gene are
usually asymptomatic. Their mature blood cells demonstrate a nonrandom pattern of X chromosome inactivation with the chromosome bearing the
normal WASP gene active in most cells.23-28
Levels of WASP in carrier PBMCs are indistinguishable from
those in unaffected individuals.
In this report we describe a female patient who presented with symptoms
resembling the WAS phenotype. The patient was heterozygous for a
WASP mutation and had a random pattern of X chromosome
inactivation in her PBMCs. WASP expression levels in the
patient's PBMCs were lower than normal, but substantially higher than
those in WAS patients, in agreement with the presence of WASP in some
of her lymphocytes and monocytes.
Blood cells
Platelet sizing
Western blots Lysates were prepared of PBMCs at 15 × 106/mL in sodium dodecyl sulfate containing the protease inhibitors diisopropylfluorophosphate (2 mM) and leupeptin (25 µg/mL; Sigma) as described.22 The lysates were electrophoresed under reducing conditions and the proteins transferred to polyvinylidene difluoride membrane (Immobilon-P; Millipore, Bedford, MA) for staining with 100 ng/mL affinity-purified rabbit antibodies to WASP C-terminal peptide (W-485) as described.22 The reactive bands were detected by 125I-labeled secondary antibodies and quantified with the Phosphorimager Storm 860 Imager and Image Quant v 1.1 program (Molecular Dynamics, Sunnyvale, CA).DNA analysis To detect WASP mutations, the 12 exons were amplified together with flanking intron regions.30 The DNA genomic template was isolated from whole blood. The amplicons were sequenced on a PE Biosystems Model 377 automatic sequencer at the Sequencing Facility of the Biopolymers Laboratory, BCMP, Harvard Medical School.RNA isolation and reverse transcriptase-polymerase chain reaction RNA was isolated from PBMCs using Trizol reagent (Gibco BRL, Gaithersburg, MD) as recommended by the manufacturer. The first-strand cDNA was synthesized by incubating 2 µg total RNA with oligodT (Promega, Madison, WI) as primer using Superscript II Reverse Transcriptase (RT; Gibco). Then, 4 µL cDNA was used to amplify nucleotides 2 through 1083 of WASP mRNA with primers W-2 and 5.24 (1 µM each)31 in 2 mM Mg2SO4, 0.2 mM dNTPs, and 2.5 U platinum Taq high-fidelity polymerase (Gibco BRL). The reaction was preincubated at 94°C for 2 minutes followed by 35 cycles at 95°C for 30 seconds, 57°C for 30 seconds, and 72°C for 1 minute. Additional extension was at 72°C for 10 minutes. Products were purified using a polymerase chain reaction (PCR) purification kit (Qiagen, Valencia, CA).X chromosome inactivation The gDNA was isolated from PBMCs. After restriction digestion with either RsaI and HpaII or RsaI only, gDNA fragments were amplified using primers flanking methylation-sensitive restriction sites in exon 1 of the androgen receptor gene.28,32 Amplified products were fractionated by electrophoresis on nondenaturing gels and detected by silver stain.Antibodies The monoclonal antibody (mAb) 5A5, which was kindly provided by Dr Shigeru Tsuchiya and Dr Shin Kawai (Department of Pediatric Oncology, Tohoku University, Sendai, Japan), was generated by immunizing mice with WASP amino acids 1-320.33 The mAb 5A5 stained WASP but not N-WASP on Western blots and did not cross-react with N-WASP.33 The epitope recognized by 5A5 was localized to amino acids 146-265. WASP antibody W-485 was raised in rabbits immunized with amino acids 485-502 (C-terminus).21 Phycoerythrin (PE)-labeled antibodies to CD3 and CD45RA, phycocyanin-5 (PC5)-labeled CD19 and mouse IgG1 antibodies were from Beckman Coulter (Fullerton, CA). Mouse IgG2a and PE-CD41 antibodies were from Caltag Laboratories (Burlingame, CA). Fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG2a antibodies were from Southern Biotechnology Associates (Birmingham, AL). Pure OKT3 (anti-CD3) was kindly provided by Dr Michael Vincent, Department of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital (Boston, MA).Flow cytometry Platelets were resuspended in platelet buffer at 0.5 × 109/mL, stained with FITC-CD41 antibody for 20 minutes at approximately 22°C and analyzed on the FACSCalibur (Becton Dickinson, San Jose, CA). A total of 20 000 CD41+ events was collected.For intracellular staining, PBMCs at 5 × 105 cells in 100 µL were fixed in 4% formaldehyde and then permeabilized with 0.1%Triton-X100 in phosphate-buffered saline (PBS) as described.33,34 Cells were blocked with 5% normal goat serum (Vector Laboratories, Burlingame, CA) and reacted with 10 µg/mL WASP 5A5 mAb or mouse IgG2a for 20 minutes on ice and washed twice with PBS, 1% fetal calf serum, 0.1% sodium azide, followed by FITC-labeled goat anti-mouse IgG2a antibodies (10 µg/mL) for 20 minutes on ice. Cells were washed and analyzed on FACSCalibur (Becton Dickinson) immediately. Where noted, PBMCs were stained before fixing with 4% formaldehyde with surface marker antibodies PE-CD3 and PC5-CD19 or PC5-CD3 and PE-CD45RA to distinguish T and B cells or naive and memory T cells. A total of 10 000 cells, which were gated based on forward and side scatter or CD3, CD19 and CD45RA markers, were recorded. The M1 area (positive fluorescence) was set so that 1% of normal cells stained positive with isotype control. Activation of T cells in vitro To obtain in vitro activated T lymphocytes, PBMCs (2 × 106/mL) were cultured in the presence of 100 ng/mL anti-CD3 mAb (OKT3), 5 µg/mL anti-CD28 mAb (Pharmingen, San Diego, CA), and 100 U/mL recombinant interleukin 2 (rIL-2; obtained through the Biological Response Modifiers Program of the National Cancer Institute) in RPMI 1640 medium containing 10% fetal calf serum, penicillin, and streptomycin (complete RPMI) for 3 days and maintained in complete RPMI supplemented with 100 U/mL rIL-2 for 9 days.
Case report The patient was born prematurely (birth weight, 2000 g). A routine blood count in the nursery revealed that she had thrombocytopenia (platelet count, 25 000/µL). Following discharge from the nursery her growth and development were normal. On several occasions she developed petechiae on her extremities. No severe infections were noted; she had otitis media on 3 occasions during the first year of life. She had no untoward reactions to routine immunizations. She never developed eczema and never had bloody diarrhea. Now in her third year of life, she bruises easily and has many posttraumatic ecchymoses. Her platelet count varies between 50 000 and 75 000/µL. She appeared to have a mild form of WAS. Her family history includes 2 suspected and 1 well-documented35 case of WAS (Figure 1).
Lymphocyte function studies The mitogenic response of lymphocytes to CD3 antibodies, concanavalin A, phytohemagglutinin, and pokeweed mitogen as well as diphtheria and tetanus antigens was decreased (Table 1) along with the number of CD3+ cells. Her serum immunoglobulin levels were within normal range. The titers of antibodies to tetanus and Haemophilus influenzae B were also normal. The levels of antibodies to several types of capsular pneumococcal polysaccharide antigens were slightly depressed (Table 1). If the patient had been male, the clinical and immune function findings would have suggested a diagnosis of mild WAS.
Platelet size Measurement of platelet size relative to standardized latex spheres showed that the effective mean diameter of the patient's platelets was 2.02 µm at age 6 months and 1.97 µm at 14 months. In contrast, the diameter of normal platelets is 2.23 ± 0.17 µm and that of nonsplenectomized WAS patients is 1.82 ± 0.10 µm.29The size of the patient's platelets was examined also by flow
cytometry of isolated platelets stained with CD41-PE mAb. Density plots showed that the patient's platelets were small (decreased forward scatter) relative to platelets of unaffected control
individuals (not shown) and those of her mother (Figure
2A).
WASP levels The patient's PBMCs were analyzed for WASP content by Western blot. WASP levels for the female patient were lower than normal (mean of 60% of normal level, 2 cell isolates; Figure 2B, lanes 1 and 2), but higher than levels in typical WAS patients, which are generally in the range 0% to 20%.22 A typical WAS patient examined in parallel had 5% of normal levels (lane 3). Levels reported for PBMCs of the female patient's affected cousin were 10% of normal.22 WASP was also examined by Western blot in platelets of the female patient. The level measured on a single isolate was 85% of normal (Figure 2C).Mutation analysis The patient's maternal cousin was known to have an acceptor site mutation in intron 6, (intervening sequence 6 [IVS6] 1G>A).35 Sequencing of this region of the patient's
DNA showed 2 peaks at position 1 of intron 6 representing nucleotides
G and A, demonstrating that the patient is heterozygous for the splice
site mutation in intron 6 (Figure 3). The
possibility of an additional WASP mutation on the patient's
paternal X chromosome was rendered unlikely by sequencing all 12 exons, all intron borders, and the near promoter region. No additional
mutation was found. Reverse transcription of RNA isolated from the
patient's PBMCs followed by amplification and sequencing showed only
normal WASP sequence, indicating the absence of detectable
levels of alternative splice products.
X chromosome inactivation X chromosome inactivation studies of PBMCs showed that the patient's mother, as anticipated for WAS carriers, had only one allele amplified after HpaII digestion, consistent with preferential inactivation of her X chromosome bearing the WASP mutation (Figure 4). In contrast, PBMCs of the female patient showed 2 bands after HpaII digestion, corresponding to active paternally and maternally derived alleles and indicating a random pattern of X inactivation in her mature blood cells (Figure 4).
WASP expression examined by flow cytometry The PBMCs of the patient and her mother were examined by flow cytometry after intracellular staining with WASP mAb 5A5.34 For the patient's mother all lymphocytes and most monocytes were WASPbright (Figure 5, second panel). In contrast, lymphocytes and monocytes of the patient were detected as both WASPbright and WASPdim populations (Figure 5, top panel). Moreover, the ratio of WASPbright and WASPdim differed for lymphocytes and monocytes. The patient's lymphocytes were highly skewed in favor of the WASPbright population. Only approximately 30% of lymphocytes, but 65% of monocytes, were WASPdim (Figure 5). A minor population of WASPdim monocytes was noted for the mother. As a control, PBMCs examined for 2 typical WAS patients (intron 8, (+2) GAGT del and exon 10, T1055ins) showed only WASPdim lymphocytes and monocytes (data not shown).
The PBMCs of additional carrier females in the patient's family were also stained with mAb 5A5. The patient's cousin and grandmother showed single populations of WASPbright lymphocytes and monocytes (Figure 5, third and fourth panels). The small population of WASPdim monocytes noted for the mother was not detected for the cousin or grandmother (Figure 5) or for unaffected control females (data not shown). To further analyze the expression of WASP, subpopulations of the
patient's lymphocytes were identified by surface staining with mAbs to
CD3, CD45RA, and CD19 prior to intracellular staining with WASP mAb
5A5. Whereas the patient's naive T cells
(CD3+CD45RA+) consisted of both
WASPbright and WASPdim cells, her memory T
cells (CD3+CD45RA
In addition, activated T lymphocytes
(CD3+CD45RA
We describe data on a 14-month-old girl with symptoms of WAS-like
disease and random X inactivation in blood cells. WASP levels in the
patient's PBMCs and platelets are intermediate between normal levels
and those of WAS patients. Sequencing of intron 6 revealed
heterozygosity for the acceptor site mutation, (IVS6 The demonstration that this patient has both thrombocytopenia and
small-sized platelets is significant because decreased platelet volume
is prominent among the criteria used to support diagnosis of
WAS.29 The patient's mother, also a WAS carrier, has
normal platelet number and size. Sizing analysis showed that the
patient's platelets are smaller than normal but larger than platelets
from WAS patients. Although we were not able to detect 2 populations of
platelets, the intermediate size and presence of 85% of normal WASP
levels in platelets suggest that the female patient has
WASP+ and WASP Female carriers of WAS have nonrandom X chromosome inactivation in blood cells and are disease-free due to preferential maturation/survival of cells with the X chromosome bearing the wild-type gene.23-28 This selection process occurs at the early stages of hematopoietic development.27,28 Previous reports have described other female patients with WAS symptoms.36-40 Theoretically, expression of disease in a female heterozygous for a WASP mutation could result from abnormalities at either of 2 levels: (1) in the mechanism of transcriptional X chromosome silencing in hematopoietic stem cells or (2) in the subsequent process that leads to preferential survival and expansion of cells that bear the active wild-type X chromosome.41 In a previously reported case that was examined at the molecular level, a female heterozygous for a WASP mutation had symptoms of classical WAS and a nonrandom pattern of X inactivation.40 The WASP mutation resided on her paternally derived chromosome, which was active in all blood cells. The authors hypothesized that the patient's disease was due to defect in the patient's maternal XIST gene, which is required to be expressed on the inactive X chromosome. Mutation in the XIST gene on one X chromosome can cause nonrandom X chromosome inactivation.42 In contrast, for the patient in the present study, the maternal X chromosome with the WASP mutation and paternal X chromosome with wild-type WASP are each active in a subpopulation of her blood cells (Figure 4), suggesting that the patient's disease is not due to a defect in the XIST-mediated transcriptional silencing process. Rather, the findings suggest that the defect is at the level of subsequent events that normally lead to proliferation/survival disadvantage of blood cells bearing the active mutant X chromosome. A potential explanation for the random X inactivation pattern in the patient is the presence of a second defect on her paternal X chromosome. This possibility is considered unlikely because no second WASP mutation was found on sequencing the entire gene. Also WASP is expressed at approximately normal levels in some of her cells. Moreover, no symptoms consistent with any other X-linked disease were noted in the female patient or her father. In addition to the Western blots showing intermediate WASP levels in
her PBMCs, analysis by flow cytometry showed that lymphocytes and
monocytes of the female patient include both WASP The significance of the minor population of WASPdim monocytes in the patient's mother, but not in other carrier females in the family, is not understood. Small populations of WASPdim monocytes have been reported for other disease-free female carriers of WASP mutations.43 In that study, WASPdim cells constituted 20% or less of total monocytes for 7 of the carriers, and these females had only WASPbright lymphocytes, suggesting that the proliferation/survival disadvantage of cells with active X chromosomes bearing WASP mutations is less selective in monocytes than in lymphocytes. However, 2 female carriers of WASP missense mutations, which cause mild disease in patients, had substantial WASPdim monocyte subpopulations (30%, 50%) and measurable WASPdim lymphocyte subpopulations, suggesting that the stringency of selection depends also on the severity of the mutation. In contrast to the 2 latter mild mutations, the mutation in the present study causes severe disease and is expected to lead to stringent selection. The stringency of lymphocyte selection is further reinforced by the
finding that the female patient's naive circulating T cells included
both WASP Certain of the findings for the female patient echo those recently reported for a WAS patient with a reversion of his missense mutation in a subfraction of his T cells. In the revertant patient, naive T cells consisted of WASPdim and WASPbright subpopulations, whereas memory T cells were WASPbright.44 Selection against the mutant WASP allele during activation/terminal T-cell differentiation, evident in the female patient and the male revertant patient, may serve in disease-free carriers as a silent backup mechanism or checkpoint. Although the female patient and her mother are heterozygous for the same WASP mutation, the mother is a disease-free WAS carrier, and the daughter has symptoms of the disease. The fact that patient's mature blood cells bearing a severe WASP mutation on active X chromosome survive hematopoietic selection processes appears to be responsible for the development of symptoms of WAS. The cumulative findings suggest that the patient's phenotype is due to an abnormality of postsilencing hematopoietic cell selection process at the level of stem cells and early progenitor cells rather than an abnormality of XIST-mediated transcriptional X chromosome silencing mechanism. As a result of defective selection, lymphocytes, monocytes, and platelets expressing the defective WASP gene survive and contribute to the development of the disease.
We are grateful to the family of the patient for their cooperation in providing blood samples and pedigree information and to Dr Charles Davis, who cares for the patient, for his cooperation. We thank Dr Shigeru Tsuchiya and Dr Shin Kawai (Department of Pediatric Oncology, Tohoku University, Sendai, Japan) for providing 5A5 monoclonal antibody. We thank Susan Mitchell and Rosanne Stein (CBR Laboratories, Boston, MA) for X chromosome inactivation analysis. We thank Dr William Strauss (Harvard Institute of Human Genetics) for clinical data, advice, and helpful discussion and Dr Michael Vincent for providing OKT3 antibody. We are grateful to Dr Peter Nigrovic for providing immunologic values of the patient.
Submitted February 2, 2002; accepted June 3, 2002.
Prepublished online as Blood First Edition Paper, June 14, 2002; DOI 10.1182/blood-2002-02-0388.
Supported by National Institutes of Health grants HL59561, AI39574, and GCRC RR02172.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Eileen Remold-O'Donnell, The Center for Blood Research, 800 Huntington Ave, Boston, MA 02115; e-mail: remold{at}cbr.med.harvard.edu.
1. Wiskott A. Familiarer, angeborener Morbus Welhofii? Monatsschr Kinderheilkd. 1937;68:212-216.
2.
Aldrich RA, Steinberg AG, Campbell DC.
Pedigree demonstrating a sex-linked recessive condition characterized by draining ears, eczematoid dermatitis and bloody diarrhea.
Pediatrics.
1954;13:133-139 3. Ochs HD. The Wiskott-Aldrich syndrome. Springer Semin Immunopathol. 1998;19:435-458[CrossRef][Medline] [Order article via Infotrieve]. 4. Perry GS III, Spector BD, Schuman LM, et al. The Wiskott-Aldrich syndrome in the United States and Canada (1892-1979). J Pediatr. 1980;97:72-78[CrossRef][Medline] [Order article via Infotrieve]. 5. Cotelingam JD, Witebsky FG, Hsu SM, Blaese RM, Jaffe ES. Malignant lymphoma in patients with the Wiskott-Aldrich syndrome. Cancer Invest. 1985;3:515-522[Medline] [Order article via Infotrieve]. 6. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr. 1994;125:876-885[CrossRef][Medline] [Order article via Infotrieve].
7.
Ochs HD, Slichter SJ, Harker LA, Von Behrens WE, Clark RA, Wedgwood RJ.
The Wiskott-Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets.
Blood.
1980;55:243-252 8. Cooper MD, Chae HP, Lowman JT, Krivit W, Good RA. Wiskott-Aldrich syndrome. An immunologic deficiency disease involving the afferent limb of immunity. Am J Med. 1968;44:499-513[CrossRef][Medline] [Order article via Infotrieve]. 9. Blaese RM, Strober W, Brown RS, Waldmann TA. The Wiskott-Aldrich syndrome. A disorder with a possible defect in antigen processing or recognition. Lancet. 1968;1:1056-1061[CrossRef][Medline] [Order article via Infotrieve].
10.
Oppenheim JJ, Blaese RM, Waldmann TA.
Defective lymphocyte transformation and delayed hypersensitivity in Wiskott-Aldrich syndrome.
J Immunol.
1970;104:835-844 11. Ammann AJ, Schiffman G, Austrian R. The antibody responses to pneumococcal capsular polysaccharides in aged individuals. Proc Soc Exp Biol Med. 1980;164:312-316[CrossRef][Medline] [Order article via Infotrieve]. 12. Lum LG, Tubergen DG, Corash L, Blaese RM. Splenectomy in the management of the thrombocytopenia of the Wiskott-Aldrich syndrome. N Engl J Med. 1980;302:892-896[Abstract].
13.
Corash L, Shafer B, Blaese RM.
Platelet-associated immunoglobulin, platelet size, and the effect of splenectomy in the Wiskott-Aldrich syndrome.
Blood.
1985;65:1439-1443 14. Shcherbina A, Rosen FS, Remold-O'Donnell E. Pathological events in platelets of Wiskott-Aldrich syndrome patients. Br J Haematol. 1999;106:875-883[CrossRef][Medline] [Order article via Infotrieve]. 15. Kwan SP, Lehner T, Hagemann T, et al. Localization of the gene for the Wiskott-Aldrich syndrome between two flanking markers, TIMP and DXS255, on Xp11.22-Xp11.3. Genomics. 1991;10:29-33[CrossRef][Medline] [Order article via Infotrieve]. 16. Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell. 1994;78:635-644[CrossRef][Medline] [Order article via Infotrieve]. 17. Symons M, Derry JM, Karlak B, et al. Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization. Cell. 1996;84:723-734[CrossRef][Medline] [Order article via Infotrieve]. 18. Higgs HN, Pollard TD. Regulation of actin filament network formation through Arp2/3 complex: activation by a diverse array of proteins. Annu Rev Biochem. 2001;70:649-676[CrossRef][Medline] [Order article via Infotrieve].
19.
Zhu Q, Watanabe C, Liu T, et al.
Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype.
Blood.
1997;90:2680-2689 20. Lemahieu V, Gastier JM, Francke U. Novel mutations in the Wiskott-Aldrich syndrome protein gene and their effects on transcriptional, translational, and clinical phenotypes. Hum Mutat. 1999;14:54-66[CrossRef][Medline] [Order article via Infotrieve]. 21. Remold-O'Donnell E, Cooley J, Shcherbina A, et al. Variable expression of WASP in B cell lines of Wiskott-Aldrich syndrome patients. J Immunol. 1997;158:4021-4025[Abstract].
22.
Shcherbina A, Rosen FS, Remold-O'Donnell E.
WASP levels in platelets and lymphocytes of Wiskott-Aldrich syndrome patients correlate with cell dysfunction.
J Immunol.
1999;163:6314-6320 23. Gealy WJ, Dwyer JM, Harley JB. Allelic exclusion of glucose-6-phosphate dehydrogenase in platelets and T lymphocytes from a Wiskott-Aldrich syndrome carrier. Lancet. 1980;1:63-65[CrossRef][Medline] [Order article via Infotrieve].
24.
Prchal JT, Carroll AJ, Prchal JF, et al.
Wiskott-Aldrich syndrome: cellular impairments and their implication for carrier detection.
Blood.
1980;56:1048-1054
25.
Fearon ER, Kohn DB, Winkelstein JA, Vogelstein B, Blaese RM.
Carrier detection in the Wiskott Aldrich syndrome.
Blood.
1988;72:1735-1739 26. Greer WL, Kwong PC, Peacocke M, Ip P, Rubin LA, Siminovitch KA. X-chromosome inactivation in the Wiskott-Aldrich syndrome: a marker for detection of the carrier state and identification of cell lineages expressing the gene defect. Genomics. 1989;4:60-67[CrossRef][Medline] [Order article via Infotrieve]. 27. Mantuano E, Candotti F, Giliani S, et al. Analysis of X-chromosome inactivation in bone marrow precursors from carriers of Wiskott-Aldrich syndrome and X-linked severe combined immunodeficiency: evidence that the Wiskott-Aldrich gene is expressed prior to granulocyte-macrophage colony-forming-unit. Immunodeficiency. 1993;4:271-276[Medline] [Order article via Infotrieve].
28.
Wengler G, Gorlin JB, Williamson JM, Rosen FS, Bing DH.
Nonrandom inactivation of the X chromosome in early lineage hematopoietic cells in carriers of Wiskott-Aldrich syndrome.
Blood.
1995;85:2471-2477 29. Kenney DM. Wiskott-Aldrich syndrome and related X-linked thrombocytopenia. Curr Opin Pediatr. 1990;2:931-934[CrossRef]. 30. Jones LN, Lutskiy MI, Cooley J, Kenney DM, Rosen FS, Remold-O'Donnell E. A novel protocol to identify mutations in patients with the Wiskott-Aldrich syndrome. Blood Cells Mol Dis. 2002;28:392-398[CrossRef][Medline] [Order article via Infotrieve].
31.
Zhu Q, Zhang M, Blaese RM, et al.
The Wiskott-Aldrich syndrome and X-linked congenital thrombocytopenia are caused by mutations of the same gene.
Blood.
1995;86:3797-3804 32. Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet. 1992;51:1229-1239[Medline] [Order article via Infotrieve]. 33. Kawai S, Minegishi M, Ohashi Y, et al. Flow cytometric determination of intracytoplasmic Wiskott-Aldrich syndrome protein in peripheral blood lymphocyte subpopulations. J Immunol Methods. 2002;260:195-205[CrossRef][Medline] [Order article via Infotrieve].
34.
Kanegane H, Nomura K, Miyawaki T, et al.
X-linked thrombocytopenia identified by flow cytometric demonstration of defective Wiskott-Aldrich syndrome protein in lymphocytes.
Blood.
2000;95:1110-1111
35.
Kwan SP, Hagemann TL, Blaese RM, Knutsen A, Rosen FS.
Scanning of the Wiskott-Aldrich syndrome (WAS) gene: identification of 18 novel alterations including a possible mutation hotspot at Arg86 resulting in thrombocytopenia, a mild WAS phenotype.
Hum Mol Genet.
1995;4:1995-1998 36. Tornai I, Kiss A, Laczko J. Wiskott-Aldrich syndrome in a heterozygous carrier woman. Eur J Haematol. 1989;42:501-502[Medline] [Order article via Infotrieve]. 37. Lin CY, Hsu HC. Acute immune complex mediated glomerulonephritis in a Chinese girl with Wiskott-Aldrich syndrome variant. Ann Allergy. 1984;53:74-78[Medline] [Order article via Infotrieve]. 38. Russell SJ, Nisen PD. Random X chromosome inactivation in a female with a variant of Wiskott- Aldrich syndrome. Br J Haematol. 1995;90:210-212[Medline] [Order article via Infotrieve].
39.
Conley ME, Wang WC, Parolini O, Shapiro DN, Campana D, Siminovitch KA.
Atypical Wiskott-Aldrich syndrome in a girl.
Blood.
1992;80:1264-1269
40.
Parolini O, Ressmann G, Haas OA, et al.
X-linked Wiskott-Aldrich syndrome in a girl.
N Engl J Med.
1998;338:291-295
41.
Puck JM, Willard HF.
X inactivation in females with X-linked disease.
N Engl J Med.
1998;338:325-328 42. Plenge RM, Hendrich BD, Willard HF. A mutation in the XIST promoter in a family with non-random X chromosome inactivation. Am J Hum Genet. 1995;57:A30.
43.
Yamada M, Ariga T, Kawamura N, et al.
Determination of carrier status for the Wiskott-Aldrich syndrome by flow cytometric analysis of Wiskott-Aldrich syndrome protein expression in peripheral blood mononuclear cells.
J Immunol.
2000;165:1119-1122
44.
Wada T, Schurman SH, Otsu M, et al.
Somatic mosaicism in Wiskott-Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism.
Proc Natl Acad Sci U S A.
2001;98:8697-8702
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  M. I. Lutskiy, F. S. Rosen, and E. Remold-O'Donnell Genotype-Proteotype Linkage in the Wiskott-Aldrich Syndrome J. Immunol., July 15, 2005; 175(2): 1329 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Wada, S. H. Schurman, G. J. Jagadeesh, E. K. Garabedian, D. L. Nelson, and F. Candotti Multiple patients with revertant mosaicism in a single Wiskott-Aldrich syndrome family Blood, September 1, 2004; 104(5): 1270 - 1272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Konno, T. Wada, S. H. Schurman, E. K. Garabedian, M. Kirby, S. M. Anderson, and F. Candotti Differential contribution of Wiskott-Aldrich syndrome protein to selective advantage in T- and B-cell lineages Blood, January 15, 2004; 103(2): 676 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Takada, H. Kanegane, A. Nomura, K. Yamamoto, K. Ihara, Y. Takahashi, S. Tsukada, T. Miyawaki, and T. Hara Female agammaglobulinemia due to the Bruton tyrosine kinase deficiency caused by extremely skewed X-chromosome inactivation Blood, January 1, 2004; 103(1): 185 - 187. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
) are all WASPbright.
After activation in vitro of T cells, all cells exhibited
CD3+CD45RA
